Oric Pharmaceuticals, Inc. financial data

Symbol
ORIC on Nasdaq
Industry
Pharmaceutical Preparations
Location
240 E. Grand Ave., 2 Nd Floor, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 18, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.44K % +8.96%
Debt-to-equity 9.38 % -13%
Return On Equity -44.5 % -4.29%
Return On Assets -40.7 % -5.63%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71M shares
Common Stock, Shares, Outstanding 71M shares +29.4%
Entity Public Float 471M USD +13.6%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 69.7M shares +35.5%
Weighted Average Number of Shares Outstanding, Diluted 69.7M shares +35.5%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 28.8M USD +12.6%
Operating Income (Loss) -143M USD -29%
Nonoperating Income (Expense) 15M USD +49.2%
Net Income (Loss) Attributable to Parent -128M USD -27%
Earnings Per Share, Basic -1.83 USD/shares +6.63%
Earnings Per Share, Diluted -1.83 USD/shares +6.63%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 59.4M USD +154%
Assets, Current 262M USD +23.4%
Property, Plant and Equipment, Net 2.92M USD +2.17%
Operating Lease, Right-of-Use Asset 8.38M USD -8.36%
Other Assets, Noncurrent 8.97M USD -7.51%
Assets 274M USD +8.78%
Accounts Payable, Current 1.55M USD +64%
Accrued Liabilities, Current 23.3M USD +19.4%
Liabilities, Current 24.8M USD +21.4%
Operating Lease, Liability, Noncurrent 6.17M USD -17.3%
Other Liabilities, Noncurrent 6.17M USD -17.3%
Liabilities 31M USD +11.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 379K USD +46.9%
Retained Earnings (Accumulated Deficit) -563M USD -29.4%
Stockholders' Equity Attributable to Parent 243M USD +8.49%
Liabilities and Equity 274M USD +8.78%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -30.2M USD -46.3%
Net Cash Provided by (Used in) Financing Activities 125M USD
Net Cash Provided by (Used in) Investing Activities -61.9M USD -584%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 71M shares +29.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 33M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 59.9M USD +151%
Deferred Tax Assets, Valuation Allowance 173M USD +29.8%
Deferred Tax Assets, Gross 175M USD +29.1%
Operating Lease, Liability 9.36M USD -8.38%
Depreciation 261K USD +3.16%
Payments to Acquire Property, Plant, and Equipment 218K USD -29.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -128M USD -28.8%
Lessee, Operating Lease, Liability, to be Paid 10.6M USD -12%
Property, Plant and Equipment, Gross 10.4M USD +11.2%
Operating Lease, Liability, Current 3.18M USD +15.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.46M USD +29.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.3M USD +15.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.22M USD -32.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.77M USD +3.51%
Deferred Tax Assets, Operating Loss Carryforwards 90.7M USD +19.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 3.74M USD +32.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.05M USD -62.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.59M USD -3.43%
Share-based Payment Arrangement, Expense 20.2M USD +32.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%